Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

0.93

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

3.1

EPS This/Next Y

Price

4.39

Target Price

21.5

Analyst Recom

1

Performance Q

-13.98

Relative Volume

1.39

Beta

1.24

Ticker: LPCN




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2024-12-19LPCN4.74N/AN/A0
2024-12-20LPCN4.86N/AN/A0
2024-12-23LPCN4.91N/AN/A0
2024-12-24LPCN4.82N/AN/A0
2024-12-26LPCN4.68N/AN/A0
2024-12-27LPCN4.83N/AN/A0
2024-12-30LPCN4.52N/AN/A0
2024-12-31LPCN4.88N/AN/A0
2025-01-02LPCN4.91N/AN/A0
2025-01-03LPCN5.0355N/AN/A0
2025-01-06LPCN5.06N/AN/A0
2025-01-07LPCN5.2626N/AN/A0
2025-01-08LPCN5.3N/AN/A0
2025-01-09LPCN5.23N/AN/A0
2025-01-10LPCN4.86N/AN/A0
2025-01-13LPCN4.6963N/AN/A0
2025-01-14LPCN4.64N/AN/A0
2025-01-15LPCN4.72N/AN/A0
2025-01-16LPCN4.5N/AN/A0
2025-01-17LPCN4.4805N/AN/A0
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2024-12-19LPCN4.78- - 0.00
2024-12-20LPCN4.86- - 0.00
2024-12-23LPCN4.80- - 0.00
2024-12-24LPCN4.90- - 0.00
2024-12-26LPCN4.72- - 0.00
2024-12-27LPCN4.57- - 0.00
2024-12-30LPCN4.67- - 0.00
2024-12-31LPCN4.94- - 0.00
2025-01-02LPCN4.87- - 0.00
2025-01-03LPCN5.06- - 0.00
2025-01-06LPCN5.07- - 0.00
2025-01-07LPCN5.35- - 0.00
2025-01-08LPCN5.23- - 0.00
2025-01-09LPCN5.23- - 0.00
2025-01-10LPCN4.89- - 0.00
2025-01-13LPCN4.74- - 0.00
2025-01-14LPCN4.59- - 0.00
2025-01-15LPCN4.62- - 0.00
2025-01-16LPCN4.50- - 0.00
2025-01-17LPCN4.39- - 0.00
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2024-12-19LPCN0.002.421.19
2024-12-20LPCN0.002.421.19
2024-12-23LPCN0.002.421.19
2024-12-24LPCN0.002.421.19
2024-12-26LPCN0.002.421.18
2024-12-27LPCN0.002.421.18
2024-12-30LPCN0.002.421.18
2024-12-31LPCN0.002.421.18
2025-01-02LPCN0.002.421.18
2025-01-03LPCN0.002.421.18
2025-01-06LPCN0.002.401.18
2025-01-07LPCN0.002.401.18
2025-01-08LPCN0.002.401.18
2025-01-09LPCN0.002.401.18
2025-01-10LPCN0.002.401.18
2025-01-13LPCN0.002.400.93
2025-01-14LPCN0.002.400.93
2025-01-15LPCN0.002.400.93
2025-01-16LPCN0.002.400.93
2025-01-17LPCN0.002.400.93
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

2.4

Beta

1.24

Average Sales Estimate Current Quarter

1

Average Sales Estimate Next Quarter

Fair Value

Quality Score

28

Growth Score

26

Sentiment Score

7

Actual DrawDown %

89.3

Max Drawdown 5-Year %

-93.9

Target Price

21.5

P/E

Forward P/E

PEG

P/S

3.01

P/B

1.22

P/Free Cash Flow

EPS

-0.76

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-52.26

Relative Volume

1.39

Return on Equity vs Sector %

-40.3

Return on Equity vs Industry %

-27.7

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Lipocine Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 17
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.
stock quote shares LPCN – Lipocine Inc Stock Price stock today
news today LPCN – Lipocine Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch LPCN – Lipocine Inc yahoo finance google finance
stock history LPCN – Lipocine Inc invest stock market
stock prices LPCN premarket after hours
ticker LPCN fair value insiders trading